DOP2014000140A - Preparaciones que comprenden emodépsido amorfo - Google Patents

Preparaciones que comprenden emodépsido amorfo

Info

Publication number
DOP2014000140A
DOP2014000140A DO2014000140A DO2014000140A DOP2014000140A DO P2014000140 A DOP2014000140 A DO P2014000140A DO 2014000140 A DO2014000140 A DO 2014000140A DO 2014000140 A DO2014000140 A DO 2014000140A DO P2014000140 A DOP2014000140 A DO P2014000140A
Authority
DO
Dominican Republic
Prior art keywords
preparations
emodépsido
amorfo
understanding
emiopside
Prior art date
Application number
DO2014000140A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Peter Kleinebudde
Petra Lange
Hans-Jürgen Hamann
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of DOP2014000140A publication Critical patent/DOP2014000140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La invención se refiere a preparaciones que comprenden emodépsido amorfo en una matriz de polivinilpirrolidona, a productos farmacéuticosque comprenden tales preparaciones y a su uso contra endoparásitos en animales o seres humanos.
DO2014000140A 2011-12-21 2014-06-17 Preparaciones que comprenden emodépsido amorfo DOP2014000140A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11194878 2011-12-21

Publications (1)

Publication Number Publication Date
DOP2014000140A true DOP2014000140A (es) 2014-07-31

Family

ID=47358491

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000140A DOP2014000140A (es) 2011-12-21 2014-06-17 Preparaciones que comprenden emodépsido amorfo

Country Status (24)

Country Link
US (3) US9539331B2 (es)
EP (1) EP2793861B1 (es)
JP (1) JP6185930B2 (es)
KR (2) KR101978620B1 (es)
CN (2) CN108187028A (es)
AU (2) AU2012357848C1 (es)
BR (1) BR112014014973A2 (es)
CA (1) CA2859787C (es)
CL (1) CL2014001637A1 (es)
CO (1) CO6990713A2 (es)
CR (1) CR20140293A (es)
DO (1) DOP2014000140A (es)
EC (1) ECSP14005917A (es)
ES (1) ES2734352T3 (es)
HK (1) HK1255536A1 (es)
IL (1) IL233183B (es)
MX (2) MX356094B (es)
MY (2) MY175307A (es)
NI (1) NI201400065A (es)
PH (2) PH12014501438B1 (es)
RU (2) RU2761529C2 (es)
UA (1) UA115232C2 (es)
WO (1) WO2013092558A1 (es)
ZA (1) ZA201404529B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101978620B1 (ko) 2011-12-21 2019-08-28 바이엘 파마 악티엔게젤샤프트 무정형 에모뎁시드를 함유하는 제제
RS62130B1 (sr) 2015-05-20 2021-08-31 Boehringer Ingelheim Animal Health Usa Inc Antihelmintička depsipeptidna jedinjenja
WO2017096530A1 (zh) * 2015-12-08 2017-06-15 广州中科蓝华生物科技有限公司 癸氧喹酯固体分散体、其制备方法和用途
EP3397638B1 (en) 2015-12-28 2023-08-23 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
BR112019009977A2 (pt) 2016-11-16 2019-08-27 Boehringer Ingelheim Animal Health Usa Inc compostos depsipeptídicos anti-helmínticos
CN114195732A (zh) * 2022-01-04 2022-03-18 丽珠集团福州福兴医药有限公司 一种艾默德斯的单晶型iii及其制备方法
CN115444927B (zh) * 2022-09-19 2023-06-02 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 艾默德斯在制备治疗三阴性乳腺癌的药物中的应用
WO2025233804A1 (en) * 2024-05-07 2025-11-13 Animol Discovery, Inc. Method of treating heartworm with emodepside

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0634408T3 (da) 1992-03-17 2002-04-22 Fujisawa Pharmaceutical Co Depsipeptidderivater, fremstilling og anvendelse deraf
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10031044A1 (de) 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RU2315614C1 (ru) * 2006-04-19 2008-01-27 Бийтемир Ахмедович Султанбеков Средство "грепол" и способ применения его при паразитарных заболеваниях
MX2009007482A (es) * 2007-02-09 2009-08-13 Pfizer Ltd Agentes antiparasitarios.
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US20120046315A1 (en) * 2008-11-14 2012-02-23 Katrin Rimkus Intermediate and oral administrative formats containing lenalidomide
DE102009012423A1 (de) 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
KR101978620B1 (ko) 2011-12-21 2019-08-28 바이엘 파마 악티엔게젤샤프트 무정형 에모뎁시드를 함유하는 제제

Also Published As

Publication number Publication date
KR20140107296A (ko) 2014-09-04
US20180153957A1 (en) 2018-06-07
MX368209B (es) 2019-09-24
CO6990713A2 (es) 2014-07-10
RU2014129620A (ru) 2016-02-10
IL233183B (en) 2020-01-30
RU2018105003A (ru) 2019-02-22
BR112014014973A8 (pt) 2017-06-13
US10251932B2 (en) 2019-04-09
US20170182118A1 (en) 2017-06-29
PH12014501438A1 (en) 2014-10-08
AU2012357848C1 (en) 2018-07-19
US9539331B2 (en) 2017-01-10
WO2013092558A1 (de) 2013-06-27
ZA201404529B (en) 2017-06-28
ES2734352T3 (es) 2019-12-05
JP6185930B2 (ja) 2017-08-23
RU2761529C2 (ru) 2021-12-09
MX2014007224A (es) 2014-09-22
US20140371139A1 (en) 2014-12-18
RU2651761C2 (ru) 2018-04-23
CA2859787C (en) 2020-09-08
CN108187028A (zh) 2018-06-22
NZ625817A (en) 2016-08-26
ECSP14005917A (es) 2015-12-31
PH12014501438B1 (en) 2017-09-15
CL2014001637A1 (es) 2014-11-21
CR20140293A (es) 2014-07-14
AU2012357848A1 (en) 2014-07-10
KR101979049B1 (ko) 2019-05-15
MY175307A (en) 2020-06-18
EP2793861B1 (de) 2019-05-01
CA2859787A1 (en) 2013-06-27
NI201400065A (es) 2015-12-10
MX356094B (es) 2018-05-14
KR101978620B1 (ko) 2019-08-28
AU2018202376A1 (en) 2018-04-26
AU2012357848B2 (en) 2018-01-04
BR112014014973A2 (pt) 2017-06-13
HK1255536A1 (zh) 2019-08-23
JP2015502377A (ja) 2015-01-22
MY203648A (en) 2024-07-11
IL233183A0 (en) 2014-07-31
CN104023710A (zh) 2014-09-03
KR20180084141A (ko) 2018-07-24
RU2018105003A3 (es) 2021-06-11
EP2793861A1 (de) 2014-10-29
UA115232C2 (uk) 2017-10-10
PH12018500368A1 (en) 2018-07-23
AU2018202376B2 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
CR20140293A (es) Preparaciones que comprenden emodepsido amorfo
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
CL2014002258A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.
CL2014000467A1 (es) Formulación que comprende cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados; metodo para obtener sustancia efectiva como plaguicida derivada de la formulación antes indicada.
CL2014000370A1 (es) Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
MX353827B (es) Formas de rifaximina y usos de la misma.
ECSP10010295A (es) Formulacion de anticuerpo
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
EP2874616A4 (en) TOPICAL DISINFECTION FORMULATIONS AND USES THEREOF
MX345697B (es) Formulaciones de rifaximina y usos de las mismas.
BR112013020517A2 (pt) dispositivo de segurança
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
PT2739615T (pt) Fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas e a sua utilização como medicamento
CL2014003472A1 (es) Pro-farmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida; composicion farmaceutica que los comprende; y su uso para tratar una infeccion bacteriana.
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
IL239327A0 (en) Tetrazole derivative solid dispersion, compositions comprising same and uses thereof
EP3068436A4 (en) Topical pharmaceutical, cosmetic and disinfectant compositions comprising phosphatidylcholine
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BR112013019687A2 (pt) antraquinona contendo preparações/formulações de lignina.
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”